Posted by Michael Wonder on 27 Feb 2024
Voxelotor for the treatment of patients with sickle cell disease (draft guidance)
27 February 2024 - NICE has issued further draft guidance on the use of voxelotor following an appeal hearing in October 2023.
Voxelotor, when used as monotherapy or in combination with hydroxyurea, is sill not recommended for the treatment of patients 12 years of age and older with haemolytic anaemia caused by sickle cell disease.
